New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval
Health technology assessment body NICE has also issued guidances rejecting three products.
You may also be interested in...
Orladeyo and Inrebic have been approved in Great Britain but they will not be available under the National Health Service unless their manufacturers can convince the health technology assessment body, NICE, that their products are cost-effective.
Industry group AdvaMed says its Indian code on interactions between medtech companies and health care professionals is a first for the country.
Advice on the acceptability of registry-based studies as a source of evidence for regulatory purposes is included in new guidance from the European Medicines Agency.